Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.44 |
| ▸ | CDK1 | P06493 | 7/20 | 0.43 |
| ▸ | IGF1R | P08069 | 4/20 | 0.43 |
| ▸ | SYK | P43405 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | ULK1 | O75385 | 1/20 | 0.39 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30833790 | 0.85 | IGF1R (0.44) | MAPK8CDK1IGF1RCDK19ALK | |
| SCHEMBL30833709 | 0.84 | CDK1 (0.55) | MAPK8CDK1IGF1RSYKGSK3B | |
| SCHEMBL30833768 | 0.84 | ALK (0.46) | EGFRMAPK8CDK1IGF1RSYK | |
| SCHEMBL30833786 | 0.83 | EGFR (0.48) | EGFRMAPK8CDK1IGF1RSYK | |
| SCHEMBL30833735 | 0.83 | EGFR (0.52) | EGFR | |
| SCHEMBL30833777 | 0.82 | JAK3 (0.41) | EGFRMAPK8IGF1RSYKGSK3B | |
| SCHEMBL29190630 | 0.81 | EGFR (0.54) | EGFRMAPK8CDK1IGF1RSYK | |
| SCHEMBL29190628 | 0.79 | IGF1R (0.46) | MAPK8IGF1R | |
| SCHEMBL30833634 | 0.79 | IGF1R (0.46) | MAPK8IGF1R | |
| SCHEMBL29190693 | 0.79 | GLO1 (0.54) | EGFRMAPK8CDK1IGF1RCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113896744-B | Selective EGFR inhibitor | 成都先导药物开发股份有限公司 | 2024-04-16 | — | — | CN | disclosed |